- Home
- PLBC vs CLLS Comparison
PLBC vs CLLS Comparison
Compare PLBC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLBC | CLLS |
|---|---|---|
| Founded | 1980 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 299.0M |
| IPO Year | 2005 | 2007 |
Fundamental Metrics
Financial Performance| Metric | PLBC | CLLS |
|---|---|---|
| Price | $45.56 | $4.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $55.00 | $8.50 |
| AVG Volume (30 Days) | 21.0K | ★ 133.7K |
| Earning Date | 01-14-2026 | 11-07-2025 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.23 | N/A |
| Revenue | ★ $89,868,000.00 | $82,551,000.00 |
| Revenue This Year | $21.11 | $32.58 |
| Revenue Next Year | $16.11 | $20.68 |
| P/E Ratio | $10.78 | ★ N/A |
| Revenue Growth | 12.51 | ★ 129.04 |
| 52 Week Low | $38.71 | $1.10 |
| 52 Week High | $49.47 | $5.48 |
Technical Indicators
Market Signals| Indicator | PLBC | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.43 | 56.84 |
| Support Level | $45.50 | $4.47 |
| Resistance Level | $47.03 | $5.45 |
| Average True Range (ATR) | 0.72 | 0.30 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 57.00 | 62.99 |
Price Performance
Historical ComparisonAbout PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.